Assuntos
Agonistas Adrenérgicos/uso terapêutico , Anafilaxia/prevenção & controle , Epinefrina/uso terapêutico , Custos de Cuidados de Saúde/estatística & dados numéricos , Guias de Prática Clínica como Assunto , Adolescente , Agonistas Adrenérgicos/economia , Adulto , Idoso , Anafilaxia/diagnóstico , Anafilaxia/economia , Anafilaxia/fisiopatologia , Criança , Pré-Escolar , Epinefrina/economia , Feminino , Humanos , Injeções Intramusculares , Revisão da Utilização de Seguros/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosAssuntos
Anafilaxia/tratamento farmacológico , Custos de Medicamentos , Epinefrina/administração & dosagem , Epinefrina/economia , Injeções/instrumentação , Agonistas Adrenérgicos/administração & dosagem , Agonistas Adrenérgicos/economia , Anafilaxia/economia , Broncodilatadores/administração & dosagem , Broncodilatadores/economia , Comércio , Recall de Medicamento , Humanos , Estados Unidos , Vasoconstritores/administração & dosagem , Vasoconstritores/economiaRESUMO
Anaphylaxis is a life-threatening condition, with at-risk individuals remaining at chronic high risk of recurrence. Anaphylaxis is frequently underrecognized and undertreated by healthcare providers. The first-line pharmacologic intervention for anaphylaxis is epinephrine, and guidelines uniformly agree that its prompt administration is vital to prevent progression, improve patient outcomes, and reduce hospitalizations and fatalities. Healthcare costs potentially associated with failure to provide epinephrine (hospitalizations and emergency department visits) generally exceed those of its provision. At-risk patients are prescribed epinephrine auto-injectors to facilitate timely administration in the event of an anaphylactic episode. Despite guideline recommendations that patients carry 2 auto-injectors at all times, a significant proportion of patients fail to do so, with cost of medicine cited as one reason for this lack of adherence. With the increase of high-deductible healthcare plans, patient adherence to recommendations may be further affected by increased cost sharing. The recognition and classification of epinephrine as a preventive medicine by both the US Preventive Services Task Force and insurers could increase patient access, improve outcomes, and save lives.
Assuntos
Anafilaxia/economia , Anafilaxia/prevenção & controle , Dedutíveis e Cosseguros/economia , Serviço Hospitalar de Emergência/economia , Epinefrina/administração & dosagem , Epinefrina/economia , Prevenção Secundária/economia , Agonistas Adrenérgicos/administração & dosagem , Agonistas Adrenérgicos/economia , Anafilaxia/diagnóstico , Anafilaxia/epidemiologia , Análise Custo-Benefício , Dedutíveis e Cosseguros/legislação & jurisprudência , Dedutíveis e Cosseguros/tendências , Serviço Hospitalar de Emergência/estatística & dados numéricos , Humanos , Hipersensibilidade/complicações , Hipersensibilidade/economia , Incidência , Injeções Intramusculares/economia , Injeções Intramusculares/instrumentação , Cooperação do Paciente/estatística & dados numéricos , Patient Protection and Affordable Care Act , Guias de Prática Clínica como Assunto , Fatores de Risco , Prevenção Secundária/legislação & jurisprudência , Prevenção Secundária/métodos , Autoadministração/economia , Autoadministração/métodos , Autoadministração/estatística & dados numéricos , Estados Unidos/epidemiologiaAssuntos
Agonistas Adrenérgicos/administração & dosagem , Anafilaxia/tratamento farmacológico , Epinefrina/administração & dosagem , Agonistas Adrenérgicos/sangue , Agonistas Adrenérgicos/economia , Agonistas Adrenérgicos/farmacocinética , Recursos Audiovisuais , Disponibilidade Biológica , Custos de Medicamentos , Emergências , Epinefrina/sangue , Epinefrina/economia , Epinefrina/farmacocinética , Desenho de Equipamento , Humanos , Injeções Intramusculares/instrumentação , Autoadministração/instrumentaçãoRESUMO
OBJECTIVE: To examine health care utilization measures indicating which asthma patients are appropriate for inhaled corticosteroid and long-acting beta(2)-adrenergic agonist (ICS/LABA) therapy and determine whether two ICS/LABA therapies were initiated in accordance with guidelines. RESEARCH DESIGN AND METHODS: A retrospective cohort study of commercially insured asthma patients aged > or =12 years that initiated fluticasone propionate/salmeterol (FSC) or budesonide/formoterol fumarate dihydrate (BFC) combination therapy in 2007 was conducted. Use was considered appropriate if patients met any of the following during a 1-year period before ICS/LABA initiation: ICS or leukotriene receptor antagonist (LTRA) use; an asthma-related emergency department (ED) visit or hospitalization; > or =2 oral corticosteroids (OCS) courses; or > or =6 short-acting beta(2)-adrenergic agonist (SABA) canisters. Multivariate logistic regression was used to assess factors associated with appropriate ICS/LABA use. Certain limitations inherent to the use of claims data for research apply to this study. RESULTS: Of 24,231 patients who initiated ICS/LABA therapy, 993 received BFC and 23,238 received FSC. Among all patients, 37.6% met > or =1 criteria for appropriate use. However, compared with FSC users, BFC users had a significantly higher likelihood of meeting > or =1 of these criteria (odds ratio, 2.01; 95% CI, 1.76-2.30; p < 0.001), and a higher proportion of BFC than FSC patients met 4 of the 5 appropriate use criteria. In total, 58.4% of BFC patients versus 36.7% of FSC patients met > or =1 criteria for appropriate use. Other factors associated with appropriate use included age, region, Charlson comorbidity score, number of medications, and prescriber specialty. CONCLUSION: Fewer than half of all patients fulfilled the specified criteria for being appropriate for ICS/LABA therapy. However, a significantly higher proportion of BFC than FSC users met the criteria for appropriate use of ICS/LABA therapy. These results may suggest a need for improved physician awareness of consensus guidelines for the initiation of ICS/LABA therapy.
Assuntos
Corticosteroides/administração & dosagem , Agonistas Adrenérgicos/administração & dosagem , Agonistas de Receptores Adrenérgicos beta 2 , Asma/tratamento farmacológico , Uso de Medicamentos , Cobertura do Seguro/estatística & dados numéricos , Administração por Inalação , Adolescente , Corticosteroides/economia , Agonistas Adrenérgicos/economia , Adulto , Idoso , Antiasmáticos/administração & dosagem , Antiasmáticos/economia , Asma/economia , Criança , Comércio , Quimioterapia Combinada , Uso de Medicamentos/economia , Uso de Medicamentos/estatística & dados numéricos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , População , Estudos Retrospectivos , Estados Unidos , Adulto JovemRESUMO
PURPOSE: We conducted a study of the daily cost of various ophthalmic solutions used in Japan for treating glaucoma: beta-adrenergic blockers (11 products), epinephrine (3), cholinergics (3), prostaglandins (2), and carbonic anhydrase inhibitors (2). METHODS: The total number of drops in one bottle of each solution was counted drop by drop. The cost per drop was calculated by dividing the government-controlled standard prices by the total number of drops in one bottle. The daily cost of therapy was calculated by multiplying the cost per drop by the number of drops typically used per day. RESULTS: The average cost of each preparation was calculated based on the prices and the daily usage. The daily cost of the beta-adrenergic blockers studied ranged widely, from $0.43 to $1.04. CONCLUSIONS: These data may be useful in selecting ophthalmic products for glaucoma therapy in Japan.